In January 2026, the FDA released its most significant guidance on wearable health devices in over a decade. The new General Wellness Device Framework redefines the boundary between regulated medical devices and unregulated wellness products -- and the implications affect every smartwatch, fitness tracker, and smart ring on the market.
If you wear an Apple Watch, Oura Ring, WHOOP band, Garmin watch, or any other health wearable, these rules determine which features you get, which features get delayed or pulled, and how much you can trust the health claims on the box.
This is not abstract regulatory theory. The WHOOP blood pressure warning letter, the delay of several Apple Watch health features in Europe, and the sudden disappearance of certain Garmin health claims all trace back to this framework. Here is what changed, why it matters, and what comes next.
Jan 2026
New Guidance Released
Most significant wearable rules in a decade
2 Categories
Regulatory Framework
General wellness vs medical device
$1.2B
Estimated Compliance Cost
Industry-wide over 3 years
14
Features Newly Clarified
Specific use cases addressed in guidance
What Changed in the January 2026 Guidance
The FDA's previous guidance on general wellness devices was issued in 2016 and updated modestly in 2019. It established a simple principle: devices that promote general wellness (exercise, sleep quality, relaxation) without making disease-specific claims can operate outside FDA regulation. Devices that diagnose, treat, or monitor specific diseases require FDA clearance.
The problem was that wearable technology evolved far beyond what the 2016 framework anticipated. Modern wearables blur the line between wellness and medical with features like:
- Sleep apnea detection on Apple Watch (medical or wellness?)
- Blood oxygen trending on Garmin (disease indicator or fitness metric?)
- Temperature-based illness detection on Oura (diagnosis or general awareness?)
- Stress scores derived from HRV on WHOOP (medical biomarker or wellness indicator?)
The January 2026 guidance addresses this ambiguity with three major changes.
Change 1: Clearer Definition of "Low Risk"
The new framework defines a three-tier risk classification for wellness device features:
| Tier | Definition | Examples | FDA Oversight |
|---|---|---|---|
| Tier 1: General Wellness | Features that promote healthy lifestyles without referencing specific diseases or conditions | Step counting, general sleep duration, activity reminders, mindfulness prompts, calorie estimation | No FDA oversight required |
| Tier 2: Enhanced Wellness | Features that use physiological measurements for wellness insights but could imply health status | HRV trends, SpO2 trends, skin temperature trends, resting heart rate trends, stress scores | Self-certification required; no pre-market review |
| Tier 3: Health Monitoring | Features that detect, screen for, or monitor specific diseases or health conditions | AFib detection, sleep apnea screening, hypertension notification, fall detection with emergency response, blood glucose monitoring | Full FDA clearance required (510(k) or De Novo) |
The critical innovation is Tier 2: Enhanced Wellness. Previously, these features existed in a gray zone. Companies either avoided disease-adjacent claims (hobbling their marketing) or made subtle claims and hoped the FDA would not notice. The new tier creates a legitimate pathway: you can offer SpO2 trends, HRV analysis, and similar physiological data as long as you do not claim it diagnoses a specific condition.
What Self-Certification Means
Tier 2 features require manufacturers to file a self-certification with the FDA, declaring that the feature meets the Enhanced Wellness criteria. This is not a review or approval -- it is a registration. The FDA can later challenge the classification if it believes the feature crosses into Tier 3 territory, but there is no pre-market gatekeeping. This is similar to how the FCC handles electronic device emissions certification.
Change 2: Explicit Language Requirements
The new guidance specifies exact language that wellness devices can and cannot use. This is where the rubber meets the road for marketing and app UI:
| Permitted (Tier 1-2) | Prohibited Without FDA Clearance (Tier 3) |
|---|---|
| "Track your blood oxygen trends" | "Monitor your blood oxygen levels for signs of respiratory conditions" |
| "Understand your heart rate variability patterns" | "Detect cardiac stress or arrhythmia risk" |
| "View your skin temperature trends" | "Screen for fever or infection" |
| "Your stress score is elevated today" | "You may be experiencing clinical anxiety" |
| "Your sleep quality was lower than usual" | "You may have a sleep disorder" |
| "Your resting heart rate is above your baseline" | "Your heart rate suggests a cardiovascular issue" |
The distinction is subtle but legally precise. Tier 2 features can present data and trends. They cannot make diagnostic or disease-specific interpretations of that data. The moment a feature says "you might have X condition," it becomes a Tier 3 medical device requiring FDA clearance.
Change 3: Clinical Decision Support Carve-Out
The new guidance creates a Clinical Decision Support (CDS) exemption for features that present data to healthcare providers rather than directly to consumers. If a wearable generates a health report designed for a physician to review -- rather than providing a patient-facing diagnosis -- the CDS exemption may apply, reducing the regulatory burden.
This is significant for features like Oura's health reports and Apple Watch's health record exports. As long as the device presents data for a clinician to interpret (rather than telling the patient what the data means clinically), the feature may qualify for lighter regulation.
Why This Matters for App Design
The CDS exemption incentivizes wearable companies to design features that share data with your doctor rather than tell you what is wrong. Expect to see more "share this report with your healthcare provider" prompts and fewer "you may have condition X" notifications in the next generation of wearable apps.
The WHOOP Warning Letter: A Case Study
In October 2025, the FDA issued a warning letter to WHOOP regarding its blood pressure estimation feature, which had been briefly available in the WHOOP 5.0 app. The letter is now the defining case study for the new regulatory framework.
What Happened
WHOOP added a feature in mid-2025 that used pulse waveform analysis from its optical sensor to estimate blood pressure ranges (not exact numbers, but "elevated," "normal," or "low" classifications). WHOOP marketed this as a "wellness insight" -- a Tier 1/2 feature that did not require FDA clearance.
The FDA disagreed. In its warning letter, the agency stated:
"The classification of blood pressure status into categories suggestive of hypertension or hypotension constitutes a health claim that implies the detection of a specific medical condition. This feature meets the definition of a medical device under 21 CFR 860 and requires pre-market clearance."
WHOOP removed the feature within 48 hours and issued a public statement acknowledging the FDA's position.
Why It Matters
The WHOOP case established a clear precedent under the new framework: any feature that categorizes a physiological measurement into disease-suggestive categories (even without explicit diagnosis) crosses from Tier 2 to Tier 3.
Showing a user their pulse wave data and saying "your pulse wave velocity is trending upward" = Tier 2 (Enhanced Wellness).
Showing a user their pulse wave data and saying "your blood pressure may be elevated" = Tier 3 (Health Monitoring, requires FDA clearance).
The distinction is not about the sensor or the measurement -- it is about the interpretation presented to the user.
The Lesson for All Wearable Companies
The WHOOP warning letter sent a clear message to the entire industry: you cannot use Tier 2 data to make Tier 3 claims. If your feature implies a disease state -- even indirectly through color coding (red for "elevated"), categorical labels ("high risk"), or suggestive language -- it needs FDA clearance. Several companies reportedly pulled or revised features in the weeks following the WHOOP letter.
How Each Major Brand Is Responding
The January 2026 guidance forced every wearable manufacturer to audit their features and marketing. Here is where the major players stand.
| Feature | Brand | Compliance Approach | FDA-Cleared Features | Tier 2 (Self-Certified) | Features Removed/Revised |
|---|---|---|---|---|---|
| Apple | Most aggressive FDA clearance strategy | ECG, AFib, hypertension notification, sleep apnea, fall detection, crash detection | HRV trends, SpO2 trends, cardio fitness, sleep stages | None -- Apple proactively clears features | |
| Oura | Cautious wellness-first positioning | None currently | Sleep staging, HRV trends, temperature trends, readiness score, SpO2 trends | Removed illness prediction language; revised temperature deviation wording | |
| Garmin | Athlete-focused, wellness-adjacent | None currently | Body Battery, HRV status, SpO2 trends, stress score, sleep score | Revised pulse ox marketing to remove medical implications; softened Body Battery health claims | |
| WHOOP | Revised after warning letter | None currently | HRV trends, strain score, recovery score, sleep staging, respiratory rate | Blood pressure estimation removed; stress score language revised | |
| Samsung | Selective FDA clearance | ECG, AFib (Galaxy Watch) | Sleep stages, SpO2 trends, body composition, stress tracking | Blood pressure feature remains unavailable in US (cleared in South Korea only) | |
| Fitbit/Google | Google Health integration focus | ECG, AFib (Pixel Watch) | Sleep stages, stress management score, SpO2, skin temperature | Minor wording changes to health metric descriptions |
Regulated vs Unregulated: The Complete Feature Map
Understanding which features on your wearable are FDA-cleared, self-certified under Tier 2, or completely unregulated helps you calibrate how much trust to place in each data point.
| Feature | Tier | FDA Clearance Required? | Who Has Clearance |
|---|---|---|---|
| Step counting | Tier 1 -- General Wellness | No | N/A |
| Calorie estimation | Tier 1 -- General Wellness | No | N/A |
| Activity reminders | Tier 1 -- General Wellness | No | N/A |
| Guided breathing | Tier 1 -- General Wellness | No | N/A |
| Sleep duration tracking | Tier 1 -- General Wellness | No | N/A |
| Sleep stage detection | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| HRV trends | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| SpO2 trends | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| Skin temperature trends | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| Stress score / readiness | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| Resting heart rate trends | Tier 2 -- Enhanced Wellness | Self-certification | Multiple brands |
| ECG recording | Tier 3 -- Health Monitoring | Yes -- De Novo or 510(k) | Apple, Samsung, Google, Circular |
| AFib detection | Tier 3 -- Health Monitoring | Yes -- De Novo or 510(k) | Apple, Samsung, Google, Circular |
| Hypertension notification | Tier 3 -- Health Monitoring | Yes -- De Novo | Apple |
| Sleep apnea screening | Tier 3 -- Health Monitoring | Yes -- De Novo | Apple |
| Fall detection (SOS) | Tier 3 -- Health Monitoring | Yes -- 510(k) | Apple, Samsung, Google |
| Blood glucose monitoring | Tier 3 -- Health Monitoring | Yes -- 510(k) or PMA | Dexcom, Abbott (wearable CGM) |
The Key Insight
Tier 2 features can tell you what your body is doing. Only Tier 3 features can tell you what it means clinically. When your watch says "your HRV is trending lower than usual," that is a wellness observation. When it says "you may have atrial fibrillation," that is a medical determination that required years of clinical trials and FDA review to earn the right to say.
Impact on Consumers
What You Gain
More features, faster. The Tier 2 self-certification pathway means wearable companies can ship new physiological data features without waiting years for FDA review. Expect to see new metrics like continuous blood pressure trending (without disease claims), hydration estimation, respiratory rate analysis, and metabolic rate tracking roll out over the next 12-18 months under Tier 2.
Clearer expectations. When a feature has FDA clearance (Tier 3), you know it has been clinically validated. When it is Tier 2, you know it is a wellness insight -- useful for trends, but not a diagnosis. This clarity helps you calibrate trust appropriately.
More data sharing with clinicians. The CDS exemption encourages features that generate physician-ready reports. Expect better integration between wearable apps and electronic health records, making it easier for your doctor to incorporate your wearable data into clinical decisions.
What You Lose
Some health claims are gone. Features that previously implied disease detection without FDA clearance have been softened or removed. Your Oura Ring no longer hints that a temperature spike means you are getting sick -- it just shows you the temperature data. Whether this is a loss or a correction depends on your perspective.
The FDA clearance bottleneck. Any feature that crosses into Tier 3 needs full FDA clearance, which typically takes 1-3 years. This means innovative health features -- real-time AFib monitoring from a ring, blood pressure estimation from a wristband, non-invasive glucose from a watch -- will continue to reach the market slowly, even if the technology is ready.
What Comes Next
The January 2026 guidance explicitly states that it will be reviewed and updated as technology evolves. Several areas are flagged for future rulemaking:
- AI/ML-derived health features: How to regulate continuously learning algorithms that improve post-market
- Multi-sensor fusion claims: When combining multiple Tier 2 measurements produces a Tier 3 insight
- International harmonization: Aligning US wellness device rules with EU MDR and other frameworks
- Direct-to-consumer genetic wellness devices: As genetic analysis merges with wearable data
The International Dimension
The EU's Medical Device Regulation (MDR), which took full effect in 2024, is generally stricter than the FDA's new framework. Several features that qualify as Tier 2 (self-certification) in the US require CE marking and notified body review in Europe. This is why some Apple Watch features launch in the US months before they are available in the EU -- the regulatory pathway is longer.
What This Means for Upcoming Features
Based on the new framework, here is our analysis of which anticipated wearable features will likely launch quickly (Tier 2) versus face regulatory delays (Tier 3):
| Rumored Feature | Likely Tier | Expected Timeline | Regulatory Challenge |
|---|---|---|---|
| Continuous stress tracking with cortisol estimation | Tier 2 | 2026-2027 | Low -- wellness framing avoids disease claims |
| Non-invasive blood glucose trending | Tier 3 | 2028-2030 | High -- glucose is inherently diabetes-linked |
| Hydration level estimation | Tier 2 | 2026 | Low -- general wellness metric |
| Blood pressure number display | Tier 3 | 2027-2028 | High -- WHOOP precedent; needs full clearance |
| Respiratory condition screening | Tier 3 | 2027-2028 | High -- disease-specific screening |
| Body composition analysis | Tier 2 | Already available | Low -- fitness metric framing |
| Menstrual cycle prediction | Tier 2 | Already available | Low -- wellness framing established |
| Fertility window prediction | Tier 2/3 (debated) | Varies | Medium -- reproductive health claims are sensitive |
| Medication adherence reminders | Tier 1 | 2026 | Low -- reminder function only |
| Sleep disorder screening | Tier 3 | 2027-2028 | High -- requires clinical validation |
Frequently Asked Questions
Frequently Asked Questions
Not at all. The new framework does not change what your device measures -- it changes how companies can describe those measurements. Your Apple Watch ECG is still FDA-cleared. Your Oura sleep data is still collected the same way. What changed is the language companies use to present this data and the regulatory pathway for new features.
Apple invested years and significant resources in FDA clinical trials for features like ECG and hypertension notification, obtaining formal clearance before launching them. WHOOP attempted to launch a blood pressure feature as a wellness tool without FDA clearance. The FDA determined that blood pressure categorization constitutes a medical claim requiring clearance.
In most cases, no. Companies have primarily changed the language and presentation of existing features rather than removing the underlying measurements. You may notice your app now says 'SpO2 trend' instead of 'blood oxygen level' or presents data without health interpretations it previously included.
FDA-cleared features (Tier 3) have undergone clinical trials and formal FDA review demonstrating safety and efficacy. Tier 2 self-certified features have been registered with the FDA but not reviewed -- the manufacturer certifies they meet wellness device criteria. Tier 3 features carry more clinical weight; Tier 2 features are wellness insights.
Yes, with appropriate calibration. FDA-cleared features (ECG, AFib detection, sleep apnea screening) have the strongest evidence base. Tier 2 features (HRV trends, sleep staging, stress scores) are useful for personal trend tracking but should not be used for medical decisions. Tier 1 features (step counting, activity tracking) are well-established and reliable for their intended purpose.
The FDA guidance applies only to the US market. The EU operates under its own Medical Device Regulation (MDR), which is generally stricter. Other markets have their own regulatory frameworks. Some features may be available in one market but not another -- Samsung's BP feature in South Korea but not the US is a prime example.
If an FDA-cleared feature (like Apple Watch ECG detecting possible AFib) flags a concern, contact your healthcare provider for clinical confirmation. If a Tier 2 wellness feature shows an unusual trend, use it as a conversation starter with your doctor -- not as a diagnosis. The new framework reinforces that wellness data supports, but does not replace, clinical care.
